Targeted therapies in hepatocellular carcinoma: past, present, and future

被引：1

作者：

Gujarathi, Rushabh ^{[1
]}

Franses, Joseph W. ^{[1
]}

Pillai, Anjana ^{[2
]}

Liao, Chih-Yi ^{[1
]}

机构：

[1] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA

[2] Univ Chicago, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Chicago, IL USA

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

hepatocellular carcinoma; targeted therapy; clinical trials; tyrosine kinase inhibitors; immunotherapy; GROWTH-FACTOR-BETA; RECEPTOR TYROSINE KINASES; CELL LUNG-CANCER; C-MET; TGF-BETA; LIVER-CANCER; SORAFENIB RESISTANCE; ANTITUMOR-ACTIVITY; SIGNALING PATHWAY; 1ST-LINE THERAPY;

D O I：

10.3389/fonc.2024.1432423

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeted therapies are the mainstay of systemic therapies for patients with advanced, unresectable, or metastatic hepatocellular carcinoma. Several therapeutic targets, such as c-Met, TGF-beta, and FGFR, have been evaluated in the past, though results from these clinical studies failed to show clinical benefit. However, these remain important targets for the future with novel targeted agents and strategies. The Wnt/beta-catenin signaling pathway, c-Myc oncogene, GPC3, PPT1 are exciting novel targets, among others, currently undergoing evaluation. Through this review, we aim to provide an overview of previously evaluated and potentially novel therapeutic targets and explore their continued relevance in ongoing and future studies for HCC.

引用

页数：16

共 50 条

[21] HAE therapies: past present and future
Bruce L Zuraw
Allergy, Asthma & Clinical Immunology, 6 (1)
[22] OSTEOPOROSIS THERAPIES: PAST, PRESENT AND FUTURE
Geusens, P.
RHEUMATOLOGY, 2012, 51 : I4 - I4
[23] Insulin therapies - past, present and future
Pillai, O
Panchagnula, R
DRUG DISCOVERY TODAY, 2001, 6 (20) : 1056 - 1061
[24] The past, present, and future of pacemaker therapies
Boink, Gerard J. J.
Christoffels, Vincent M.
Robinson, Richard B.
Tan, Hanno L.
TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (08) : 661 - 673
[25] Targeted Therapies in NSCLC - present and future
Pall, Georg
Hilbe, Wolfgang
WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 545 - 553
[26] Future therapies for hepatocellular carcinoma
Sangro, B
Mazzollini, G
Prieto, J
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (05) : 515 - 521
[27] Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions
Choi, Kyung-Ju
Baik, In Hye
Ye, Sang-Kyu
Lee, Yun-Han
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (07) : 986 - 991
[28] Molecular Targeted Therapy in Hepatocellular Carcinoma: Present Achievements and Future Challenges
Giacomin, Anna
Sergio, Adriana
Vanin, Veronica
Gazzola, Alessia
Cazzagon, Nora
Farinati, Fabio
DIGESTIVE DISEASES, 2012, 30 (03) : 284 - 288
[29] Molecular targeted therapies in hepatocellular carcinoma
Llovet, Josep M.
Bruix, Jordi
HEPATOLOGY, 2008, 48 (04) : 1312 - 1327
[30] Hepatocellular Carcinoma: Locoregional and Targeted Therapies
Wong, Robert
Frenette, Catherine
Gish, Robert
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2011, 40 (03) : 599 - +

← 1 2 3 4 5 →